TY - JOUR
T1 - Diagnosis for early stage knee osteoarthritis
T2 - probability stratification, internal and external validation; data from the CHECK and OAI cohorts
AU - Wang, Qiuke
AU - Runhaar, Jos
AU - Kloppenburg, Margreet
AU - Boers, Maarten
AU - Bijlsma, Johannes W. J.
AU - the CREDO expert group
AU - Bierma-Zeinstra, Sita M. A.
N1 - Funding Information:
We would like to acknowledge the CREDO experts group (N.E. Aerts-Lankhorst, R. Agricola, A.N. Bastick, R.D.W. van Bentveld, P.J. van den Berg, J. Bijsterbosch, A. de Boer, M. Boers, A.M. Bohnen, A.E.R.C.H. Boonen, P.K Bos, T.A.E.J. Boymans, H.P. Breedveldt-Boer, R.W. Brouwer, J.W. Colaris, J. Damen, G. Elshout, P.J. Emans, W.T.M. Enthoven, E.J.M. Fr?lke, R. Glijsteen, H.J.C. van der Heide, A.M. Huisman, R.D. van Ingen, M.L. Jacobs, R.P.A. Janssen, P.M. Kevenaar, M.A. van Koningsbrugge, P. Krastman, N.O. Kuchuk, M.L.A. Landsmeer, W.F. Lems, H.M.J. van der Linden, R. van Linschoten, E.A.M. Mahler, B.L. van Meer, D.E. Meuffels, W.H. Noort-van der Laan, J.M. van Ochten, J. van Oldenrijk, G.H.J. Pols, T.M. Piscaer, J.B.M. Rijkels-Otters, N. Riyazi, J.M. Schellingerhout, H.J. Schers, B.W.V. Schouten, G.F. Snijders, W.E. van Spil, S.A.G. Stitzinger, J.J. Tolk, Y.D.M. van Trier, M. Vis, V.M.I Voorbrood, B.C. de Vos, and A. de Vries) for evaluating the medical files and their feedback on the manuscript. We thank the OAI cohort research team for sharing patient data. We thank Erin Macri for checking and editing the language. This work was supported by the Dutch Arthritis Society (Project ID 15-1-301); Q. Wang was financed by China Scholarship Council (CSC) (grant number: 201906230308).
Funding Information:
This work was supported by the Dutch Arthritis Society ( Project ID 15-1-301 ); Q. Wang was financed by China Scholarship Council (CSC) ( grant number: 201906230308 ).
Funding Information:
J.R. and M.K. received research grants from the Dutch Arthritis Society; M.K. reports fee for consultancy (Abbvie, Pfizer, Levicept, GlaxoSmithKline, Merck-Serono, Kiniksa, Flexion, Galapagos, Jansen, CHDR, Novartis, UCB) and local investigator of industry-driven trial (Abbvie), from Wolters Kluwer (UptoDate), Springer Verlag (Reumatologie en klinische immunologie), grants from IMI-APPROACH, Board member OARSI, President Dutch Society Rheumatology and Member EULAR Council.
Publisher Copyright:
© 2022 The Author(s)
PY - 2022/8/1
Y1 - 2022/8/1
N2 - Objective: To internally and externally validate our diagnostic criteria of early stage knee osteoarthritis (OA) in the CHECK and OAI cohorts. Design: We applied two previously developed diagnostic models to all knees in CHECK and OAI cohorts to calculate probabilities of early stage knee OA at baseline. Knees were categorized into three groups based on probability: ‘no OA’ (probability ≤ 30%), ‘uncertain’ (probability between 30% and 70%) and ‘early stage OA’ (probability ≥ 70%). To validate the diagnosis, we obtained OA related outcome measures at 10-year follow-up in the CHECK cohort, and at 8-9-year follow-up in the OAI cohort. We compared outcome measures between ‘no OA’ and ‘early stage OA’ knees, and between ‘no OA’ and ‘uncertain’ knees using generalized estimating equations. Results: In CHECK (n = 1042 knees) both models showed ‘early stage OA’ knees presented with significant and clinically relevant higher WOMAC scores, higher Kellgren & Lawrence (KL) grade, and higher rates of joint space narrowing (JSN) progression after 10 years, compared to ‘no OA’ knees. In OAI (n = 2937 knees) both models showed ‘early stage OA’ knees presented with significant and clinically relevant higher WOMAC scores, higher KL grade, and higher rates of KL and JSN progression after 8-9 years, compared to ‘no OA’ knees. Smaller, but still significant differences between ‘uncertain’ and ‘no OA’ knees were observed in both cohorts. Conclusions: These results support internal and external validity of the two sets of diagnostic criteria for early stage knee OA.
AB - Objective: To internally and externally validate our diagnostic criteria of early stage knee osteoarthritis (OA) in the CHECK and OAI cohorts. Design: We applied two previously developed diagnostic models to all knees in CHECK and OAI cohorts to calculate probabilities of early stage knee OA at baseline. Knees were categorized into three groups based on probability: ‘no OA’ (probability ≤ 30%), ‘uncertain’ (probability between 30% and 70%) and ‘early stage OA’ (probability ≥ 70%). To validate the diagnosis, we obtained OA related outcome measures at 10-year follow-up in the CHECK cohort, and at 8-9-year follow-up in the OAI cohort. We compared outcome measures between ‘no OA’ and ‘early stage OA’ knees, and between ‘no OA’ and ‘uncertain’ knees using generalized estimating equations. Results: In CHECK (n = 1042 knees) both models showed ‘early stage OA’ knees presented with significant and clinically relevant higher WOMAC scores, higher Kellgren & Lawrence (KL) grade, and higher rates of joint space narrowing (JSN) progression after 10 years, compared to ‘no OA’ knees. In OAI (n = 2937 knees) both models showed ‘early stage OA’ knees presented with significant and clinically relevant higher WOMAC scores, higher KL grade, and higher rates of KL and JSN progression after 8-9 years, compared to ‘no OA’ knees. Smaller, but still significant differences between ‘uncertain’ and ‘no OA’ knees were observed in both cohorts. Conclusions: These results support internal and external validity of the two sets of diagnostic criteria for early stage knee OA.
KW - Early diagnosis
KW - External validation
KW - Internal validation
KW - Knee osteoarthritis
UR - http://www.scopus.com/inward/record.url?scp=85129178528&partnerID=8YFLogxK
U2 - 10.1016/j.semarthrit.2022.152007
DO - 10.1016/j.semarthrit.2022.152007
M3 - Article
C2 - 35468448
SN - 0049-0172
VL - 55
JO - Seminars in Arthritis and Rheumatism
JF - Seminars in Arthritis and Rheumatism
M1 - 152007
ER -